DALLAS, December 15, 2014 /PRNewswire/ --
ReportsnReports.com adds Ocular Disorders: Rising Therapeutics, Technologies, and Devices 2014 market research report that covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications.
This report begins with outlining Age-related macular degeneration (both wet and dry) and delving into Anti-VEGF therapies in chapter 2. Further providing substantial weight to this report, several companies were interviewed on their approach to targeting wet and dry AMD, their strategies for seeking alternative therapeutic options, and the hardships they have encountered in their research and product execution.
Report highlights include:
- Exclusive interviews from four companies (Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals) providing details of their products.
- Both invasive and noninvasive procedures are discussed, along with current treatment options and how they relate to rising therapies.
- Demographic survey and analysis of researchers working in ocular disorders including promising therapeutic options, targets of interest, and challenges encountered.
- Over 250 companies featuring clinical trials and pipeline data.
The Ocular Disorders: Rising Therapeutics, Technologies, and Devices report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications. In an interview with several companies including Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals, representatives mentioned several technologies and devices in development to improve the current line of therapeutics.
Both invasive and noninvasive procedures are discussed, along with current treatment options and how they relate to rising therapies. Specific highlights of this report include extensive research, company backgrounds, challenges, and validation techniques for therapeutic applications offered by the participating companies. These techniques include:
- Radiation therapy
- Implantable telescope technology
- PharmacoSurgery
- Mucosal penetrating products
Also available are complementary interviews with company representatives at the end of each section.
The interviewees include:
- President and CEO of Oraya Therapeutics
- Marketing Director of VisionCare Ophthalmic Technologies
- Chairman and CEO of Omeros
- CMO of Kala Pharmaceuticals
Also included in this report is a demographic survey of researchers working in ocular disorders. Some of the concepts include ocular areas of research, promising therapeutic options, targets of interest, and challenges encountered. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=274702 .
List of Tables
Table 2.1: Clinical status for common therapies for wet AMD
Table 3.1 Platform specifications
Table 4.1: Platform specifications
Table 5.1: Targets and their clinical status
Figure 6.1: Targets and their clinical status
Table 7.1: Targets in clinical stages
Table 7.2: Therapeutic platform specifications
List of Figures
Figure 8.1: Areas of research
Figure 8.2: Ocular disorders of interest
Figure 8.3: Promising therapies for ocular diseases
Figure 8.4: Promising targets for ocular therapies
Figure 8.5: Challenges encountered
The Ocular Pain - Pipeline Review, H2 2014 market research report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. Complete research spread across 59 pages and published in November 2014 is available at http://www.reportsnreports.com/reports/317532-ocular-pain-pipeline-review-h2-2014.html .
The Omeros Corporation - Product Pipeline Review-2014 report provides comprehensive information on the current therapeutic developmental pipeline of Omeros Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Get a copy of this research at http://www.reportsnreports.com/reports/311294-omeros-corporation-product-pipeline-review-2014.html .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@reportsandreports.com
Connect With Us on:
Facebook: https: //www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus:https://plus.google.com/111656568937629536321/posts
Pinterest: www.pinterest.com/comeonseo/reportsnreports/
RSS/Feeds: http: //www.reportsnreports.com/feed/l-latestreports.xml
